A recent study indicates that people who stop using blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who halt traditional lifestyle plans.
Published data in a prominent medical journal demonstrates that while overweight individuals can lose substantial amounts of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users buying these treatments need to be informed of the danger of quick rebound weight gain when the medication ends," cautioned expert Dr. Susan Jebb.
Such speed of recovery suggests a return to original weight in about one and a half years.
Analyzing Therapies
The research, which examined 37 of studies involving thousands of participants, compared the effects of the injectable medications with older methods.
Researchers note that individuals who shed pounds through lifestyle changes alone typically experience a slower weight regain—approximately 100 grams monthly—after stopping.
Understanding the Rapid Regain
Nutrition scientists suggest the mechanism of the jabs explains the amplified regain.
The injections mimic a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production might result in the body to produce less of its own natural GLP-1, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement leads to hunger is no longer kept in check, making binge eating much more probable."
A Chronic Condition?
The NHS suggest the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Professionals argue that, considering the likelihood of weight regain, the therapy is often life-long.
This opinion is supported by pharmaceutical companies, who say that the results "emphasize the long-term nature of excess weight," comparing it to managing conditions like high blood pressure.
User Accounts
People who have stopped the jabs report a sudden return of appetite.
"I experienced a trigger flipping and I was suddenly ravenous," said an individual.
This difficulty is worsened if individuals have not established lasting lifestyle or habit changes during treatment.
Widespread Adoption
Figures suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is higher among females than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
Finally, clinicians emphasize that while GLP-1 drugs are effective agents for shedding pounds, they are not a standalone solution and long-term success likely depends on integrated lifestyle support.
